跳至主要内容
临床试验/NL-OMON25189
NL-OMON25189
招募中
不适用

A phase I study to investigate the safety of TEG001 cell suspension for infusion in patients with relapsed/refractory Acute Myeloid Leukemia, high-risk Myelodysplastic Syndrome (IPSS-R score >4,5) or Multiple Myeloma

niversity Medical Center Utrecht0 个研究点目标入组 18 人开始时间: 待定最近更新:

概览

阶段
不适用
状态
招募中
入组人数
18

概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Age ¡Ý 18\-years
  • \- Relapsed/refractory Acute Myeloid Leukemia, high\-risk Myelodysplastic Syndrome (IPSS\-R score \>4,5\) or Multiple Myeloma, for which no remaining standard of care or approved treatment options are available

排除标准

  • \- In the investigators judgment, the subject is unlikely to complete all protocol\-required study visits or procedures
  • \- Central Nervous System involvement of the haematological malignancy

研究者

相似试验